Literature DB >> 1963849

Delta 9-tetrahydrocannabinol enhances presynaptic dopamine efflux in medial prefrontal cortex.

J Chen1, W Paredes, J H Lowinson, E L Gardner.   

Abstract

Acute administration of 1.0-2.0 mg/kg delta 9-tetrahydrocannabinol (delta 9-THC) increased presynaptic dopamine (DA) efflux in the medial prefrontal cortex of rats, as measured by intracerebral microdialysis in awake, behaving rats. These data are congruent with suggestions that (1) marijuana's euphorigenic effects and abuse potential may be related to augmentation of presynaptic DA mechanisms, and (2) the medial prefrontal cortex may be an important site of action for drugs of abuse in general and for delta 9-THC in particular.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1963849     DOI: 10.1016/0014-2999(90)94136-l

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  28 in total

1.  Altered dendritic distribution of dopamine D2 receptors and reduction in mitochondrial number in parvalbumin-containing interneurons in the medial prefrontal cortex of cannabinoid-1 (CB1) receptor knockout mice.

Authors:  Megan L Fitzgerald; June Chan; Kenneth Mackie; Carl R Lupica; Virginia M Pickel
Journal:  J Comp Neurol       Date:  2012-12-01       Impact factor: 3.215

Review 2.  The acute effects of cannabinoids on memory in humans: a review.

Authors:  Mohini Ranganathan; Deepak Cyril D'Souza
Journal:  Psychopharmacology (Berl)       Date:  2006-09-26       Impact factor: 4.530

3.  D(2) dopamine receptors enable delta(9)-tetrahydrocannabinol induced memory impairment and reduction of hippocampal extracellular acetylcholine concentration.

Authors:  F Nava; G Carta; A M Battasi; G L Gessa
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

4.  Modulation by fluoxetine of striatal dopamine release following Delta9-tetrahydrocannabinol: a microdialysis study in conscious rats.

Authors:  D T Malone; D A Taylor
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

5.  Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people.

Authors:  Cécile Henquet; Lydia Krabbendam; Janneke Spauwen; Charles Kaplan; Roselind Lieb; Hans-Ulrich Wittchen; Jim van Os
Journal:  BMJ       Date:  2004-12-01

Review 6.  Drug discovery strategies that focus on the endocannabinoid signaling system in psychiatric disease.

Authors:  Ryan Wyrofsky; Paul McGonigle; Elisabeth J Van Bockstaele
Journal:  Expert Opin Drug Discov       Date:  2014-12-09       Impact factor: 6.098

Review 7.  Cannabis and psychosis/schizophrenia: human studies.

Authors:  Deepak Cyril D'Souza; Richard Andrew Sewell; Mohini Ranganathan
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-07-16       Impact factor: 5.270

Review 8.  Supraspinal modulation of pain by cannabinoids: the role of GABA and glutamate.

Authors:  K Rea; M Roche; D P Finn
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

9.  Antipsychotic-induced alterations in CB1 receptor-mediated G-protein signaling and in vivo pharmacology in rats.

Authors:  Jenny L Wiley; Seth H Kendler; James J Burston; Daniel R Howard; Dana E Selley; Laura J Sim-Selley
Journal:  Neuropharmacology       Date:  2008-07-30       Impact factor: 5.250

10.  Altered striatal functional connectivity in subjects with an at-risk mental state for psychosis.

Authors:  Orwa Dandash; Alex Fornito; Jimmy Lee; Richard S E Keefe; Michael W L Chee; R Alison Adcock; Christos Pantelis; Stephen J Wood; Ben J Harrison
Journal:  Schizophr Bull       Date:  2013-07-16       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.